The demand for intraoperative blood salvage (IBS) in cancer surgery originates from the high transfusion rate, the unfavorable effects of anemia, and the special impact of transfusion risks such as immunomodulation in tumor patients. The advantages of IBS are availability, low waste rate, and excellent quality of the autologous, unstored blood. Effective elimination of tumor cell dissemination by retransfusion of wound blood can be achieved only by blood irradiation. Combining established methods of IBS and blood irradiation is feasible and allows efficient saving of blood. For Jehovah’s witnesses it may open the option of tumor surgery. From an anesthesiological point of view IBS blood is not a drug but part of the therapy. Even if it is viewed as drug, practical medicolegal regulations are in sight. IBS with blood irradiation provides the safest and best blood for optimal hemotherapy in tumor patients. In addition, first data indicate a better outcome of patients in whom IBS was performed.